PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Insights from the PVI-SHAM-AF Trial: Implications of Catheter Ablation on Symptoms in Atrial Fibrillation Patients

  • By

  • Ulrich Laufs

  • Michael Böhm

  • Felix Mahfoud

  • Rolf Wachter

  • August 30, 2026

Share

  • 1

    The PVI-SHAM-AF trial assessed catheter ablation's impact on quality of life in 262 atrial fibrillation patients over 6 months.

  • 2

    Catheter ablation reduced atrial fibrillation recurrence to 21%, compared to 41% in the sham group, indicating a significant absolute difference.

  • 3

    Despite improvements in quality of life scores in both groups, the difference between catheter ablation and sham treatment was not statistically significant.

  • 4

    The trial's findings suggest that active clinical management may significantly contribute to quality-of-life improvements in atrial fibrillation patients.

  • 5

    The study highlights that symptom burden in atrial fibrillation may involve factors beyond arrhythmia, including anxiety and depression.

Original Source(s)

PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?

  • by Ulrich Laufs, Michael Böhm, Felix Mahfoud, Rolf Wachter

  • August 30, 2026

Related Content

Myocardial function recovery in peripartum cardiomyopathy: the role of global longitudinal strain and myocardial work

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

Medical Oddities: Could multilingualism keep you young?

From multilingual minds to pomegranate hearts, gastric mischief, and swishable tea, science stays delightfully odd.